Survival and prognostic factors of patients with renal cell cancer with bone metastasis in the era of targeted therapy: A single-institution analysis
Author:
Publisher
Elsevier BV
Subject
Urology,Oncology
Reference17 articles.
1. Cancer statistics, 2016;Siegel;CA Cancer J Clin,2016
2. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study;Heng;J Clin Oncol,2009
3. Features Associated with Recurrence Beyond 5 Years After Nephrectomy and Nephron-Sparing Surgery for Renal Cell Carcinoma: Development and Internal Validation of a Risk Model (PRELANE score) to Predict Late Recurrence Based on a Large Multicenter Database (CORONA/SATURN Project)
4. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group;Manola;Clin Cancer Res,2011
5. Record-3: phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC);Motzer;J Clin Oncol,2014
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Practical management of renal cell carcinoma: integrating current approaches with advances in bone metastasis treatment;EFORT Open Reviews;2024-06-01
2. Renal cell carcinoma with multiple bone metastases effectively treated by a combination of tyrosine kinase inhibitor, robot‐assisted partial nephrectomy, and metastasectomy;Clinical Case Reports;2024-03
3. The Outcome of Molecularly Targeted Therapy after Surgical Treatment of Spinal Metastasis;Journal of Clinical Medicine;2023-06-08
4. The Construction and Validation of a new Predictive Model for Overall Survival of Clear Cell Renal Cell Carcinoma Patients with Bone Metastasis Based on Machine Learning Algorithm;Technology in Cancer Research & Treatment;2023-01
5. Current status and novel insights into the role of metastasectomy in the era of immunotherapy;Expert Review of Anticancer Therapy;2022-12-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3